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ABSTRACT
COMPUTATIONAL MODEL OF ALENDRONATE EFFECTS ON CANINE RIB
REMODELING AND MICRODAMAGE

Emily Huang

Bisphosphonates are a class of drugs used to prevent and treat bone diseases by
inhibiting the resorption of bone by osteoclasts and suppressing bone remodeling.
Osteoporosis is a bone disease that develops when bone resorption exceeds bone
formation which results in an increase in bone porosity and fracture risk. The risk for
fractures can be reduced by increasing bone mass. Alendronate is type of bisphosphonate
that is approved by the Food and Drug Administration (FDA) to treat postmenopausal
osteoporosis by suppressing basic multicellular unit (BMU) remodeling and increasing
bone mass. The long term effects of bisphosphonates are still unclear due to the
difficulty in obtaining long term data; therefore, developing a mathematical model based
on data and relationships from short term studies can be a useful method in predicting the
effects of the drug.
The purpose of this study was to develop a computer model that could simulate
the long term effects of alendronate treatment on canine rib remodeling, bone volume,
and microdamage by matching 1 and 3 year experimental data results. The experimental
effects of alendronate (ALN) were studied at the Indiana University School of Medicine.
In two separate experiments, skeletally mature female beagles were subjected to 1 and 3
year treatments of saline vehicle (CON), or one of two doses of ALN (ALN0.2 or
ALN1.0 mg/kg/day). The lower dose (ALN0.2) corresponds to the clinical dosage used
iv

to treat postmenopausal osteoporosis and the higher dose (ALN1.0) is the dose used to
treat Paget’s disease. Bone volume fraction (BV/TV), damage, and remodeling
activation frequency (Ac.f) of the rib were quantified using standard histomorphometric
techniques.
The mathematical model was developed by modifying a previous mathematical
algorithm for trabecular bone remodeling, to create an equilibrium for cortical bone
remodeling that matched the experimental control data from 1 year studies. Using the
equilibrium conditions as a baseline model, ALN was modeled by suppressing activation
frequency and reducing the resorption area. The changes in BV/TV, damage
accumulation, and Ac.f were followed for 3 years and compared to the experimental
results. The results for BV/TV, Ac.f, and damage for the 1 year model and the results for
BV/TV and damage for the 3 year model were consistent with experimental studies.
BV/TV results for both doses showed increases from 1 to 3 years with alendronate
treatment. Ac.f results for both treatment doses at 1 year and ALN1.0 at 3 years were
also within range of the experimental data; however, ALN0.2 for 3 years was not
consistent with the experimental results. While the predicted Ac.f for ALN0.2 does show
an initial decrease, it is not nearly as extreme as the results from the experimental data
and the data remains fairly constant between 1 and 3 years, which is in contrast to the
experimental results. The model also predicts damage accumulation is greatest early
during bisphosphonate treatment, due to the initial suppression of bone resorption. This
increase in microdamage accumulation was previously thought to impair the mechanical
properties of bone; however, recent experimental studies show that while the initial
increase in microdamage may contribute to alterations in bone properties at 1 year of
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treatment, other factors appear to contribute to their reduction long term. The simulation
results are consistent with the experimental data, which suggest that damage increases for
up to 1 year of treatment and then levels off thereafter. The results of the simulation
suggest that since bisphosphonates do not cause further increases in microdamage
accumulation after 1 year of treatment, ALN may not lead to increased bone fragility
associated with microdamage long term and rather, may decrease fracture risk.
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CHAPTER 1: INTRODUCTION

1.1 Properties of Bone
Bone is a dynamic structure whose properties make it ideal for structural support,
protection, mineral storage, movement, and cell formation. The properties of bone allow
it to adapt to its surrounding environment and optimize its structure in order to maintain
its light weight and strength. Bone is a specialized connective tissue made up of an
extracellular matrix (ECM) and a cellular component. The ECM is responsible for the
functional characteristics of bone tissue like structure and strength and is made up of both
organic and inorganic material. The organic material consists mostly of collagen and the
inorganic material consists primarily of hydroxyapatite or calcium phosphate crystals.
The ECM is the mineralized portion of bone and is maintained by living cells that form
the cellular component [1].

1.2 Bone tissue
Bone tissue can be classified as either cortical or trabecular bone depending on its
porosity (Figure 1). Cortical bone, also referred to as compact bone, forms a very dense
cortex around bone with porosities between 5 to 10 percent [2]. The key feature of
compact bone is a functional unit called an osteon which is made up of closely packed
concentric circular matrices called lamellae. The cylindrical geometry of an osteon makes
cortical bone more resistant to fractures because the energy required to form a crack is
dissipated along the outer cement line of the circular osteon thus slowing down and even
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stopping crack propagation. This characteristic gives cortical bone a fracture toughness
of 2.2-6.3 MPa-m1/2, elastic modulus of 17.4 GPa, and a high tensile ultimate stress of
133 MPa [1]. Enclosed in the center of an osteon is the Haversian canal which contains
nerves and blood vessels that are essential for providing nutrients and removing wastes
from the surrounding cells [2]. Compact bone also consists of Volkman’s canals and
resorption cavities. The Volkman’s canals contain blood vessels that connect the
Haversian canals to each other and to the bone surface while the resorption cavities are
temporary spaces created by osteoclasts during bone remodeling [2]. The porosity of
cortical bone is largely made up of these Haversian canals, Volkmann’s canal, and
resorption cavities (Figure 2). Trabecular bone, also called cancellous or spongy bone,
consists of a network of interconnected struts called trabeculae which are surrounded by
bone marrow (Figure 3). In contrast to cortical bone, trabecular bone consists of a more
irregular structure, making the bone more fragile with an elastic modulus of 272 ± 195
MPa and an ultimate stress of 2.54 ± 0.62 MPa [2]. Compared to cortical bone,
trabecular bone is highly porous and more loosely packed with porosities between 75 to
95 percent [2].

Figure 1. Illustration of important features in both cortical and trabecular bone [3].
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Haversian Canal

Volkmann’s Canal

Figure 2. Microphotograph of cortical bone including important features like the
osteons, Haversian canals, and Volkmann’s canals [46].

Figure 3. Microphotograph of normal trabecular bone [47].

1.3 Bone Cells
The formation of the ECM is due to a collection of bone cells that maintain the
matrix. As bone tissue is constantly being loaded, bone cells must work together to
remove any fatigue damage caused by stress in order to maintain the integrity of the bone
[2]. The cellular component of bone consists of four main cells which can be categorized
into two cell types: bone resorbing and bone forming. Cells that resorb bone are similar
6

to macrophages whose main role is to phagocytose or remove debris. Cells that form
bone are like fibroblasts, whose role is to synthesize and maintain the bone matrix. The
four bone cells are osteoclasts, osteocytes, osteoblasts, and bone lining cells (Figure 4).
Osteoclasts are multinucleated cells made in the bone marrow and are responsible
for bone resorption. The area of contact between the osteoclasts and the bone matrix
forms a ruffled or brushed border where resorption occurs. Hydrogen ions and enzymes
are released along this border to demineralize and dissolve the proteins in the matrix [1].
Osteoblasts are bone forming cells found on the border of developing bone. They
are mononucleated cells made in the bone marrow and are thought to be activated by
mechanical stress [2]. These cells produce an unmineralized matrix called osteoid which
is made primarily of type 1 collagen. The apposition rate or the rate at which the osteoid
is laid down is about 1 micrometer/day [2]. As the amount of osteoid increases, the
osteoblasts get pushed into the developing matrix and become osteocytes.
Osteocytes are mature osteoblasts located within the bone matrix and are thought
to play a role in bone turnover by sensing mechanical stress [2]. These cells are
embedded in cavities called lacunae and can communicate with other osteocytes and
osteoblasts through canals called canaliculi [1]. The canaliculi form tight gap junctions
within the bone in which nutrients and chemical signals are passed [2]. This network of
communication allows the osteocytes to transmit information and play an important role
in bone remodeling.
After osteoblasts have completed filling in a cavity, the cells flatten out and
“retire”, becoming bone lining cells [2]. Bone lining cells, like osteocytes, are made from
osteoblasts; however, unlike osteocytes, these cells do not get buried into the bone matrix
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but rather, become dormant and flatten out discontinuously against the bone surface.
Bone lining cells communicate with osteocytes through gap junctions and are thought to
regulate the movement of minerals like calcium and phosphate into and out of the bone.
These cells are also believed to be able to sense changes in mechanical stress and
chemical stimuli in order to activate the remodeling process [2].

Figure 4. Schematic of bone cells. The osteoclasts are characterized as being multinucleated
and having a ruffled border along the area of contact with the bone. Osteoblasts form bone
by producing an unmineralized bone tissue called osteoid which will later become calcified
bone matrix. Both osteocytes and bone lining cells are derived from osteoblasts and are
either embedded into the matrix (osteocytes) or flattened over the bone surface (bone lining
cells) and play a role in the remodeling process [3].

1.4 Bone Modeling and Remodeling
Wolff’s law states that bone is a dynamic structure that is able to sense
mechanical loads and adapt its structure to match the surrounding environment [2]. Bone
adaptation is accomplished by two processes called modeling and remodeling.
Bone modeling is the process where bone resorption and bone formation work
independently to “customize” the shape of bones [2]. Modeling occurs during childhood
allowing bones to sculpt themselves by removing or adding bone to form the optimal
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geometry that will support loads placed on the bone [2]. Bone modeling decreases once
the skeleton has matured while remodeling continues throughout an individual’s lifetime.
Bone remodeling is the process where bone resorption and bone formation cells
work together to form a cellular unit called a basic multicellular unit (BMU) to remove
old bone and replace it with newly formed bone [2]. Unlike modeling, remodeling
typically does not affect the shape or size of the bone, but instead repairs fatigue damage
before it leads to fracture [2]. Because remodeling occurs throughout an individual’s
lifetime, bone remodeling greatly affects the mechanical properties of bone.
Bone remodeling can be initiated by a number of factors including mechanical
stimulus, damage, and chemical factors such as hormone and calcium levels [2]. Bone is
designed to maintain homeostasis; so, when strain levels fall below normal, bone is in a
state of disuse and bone remodeling is activated in order for BMUs to remove unneeded
bone. Similarly, in an overload state, or when there is an increase in loading, remodeling
is activated to deposit more bone to maintain the integrity of the bone. Remodeling can
also be initiated by cyclic loading which can cause fatigue damage in the form of
microcracks that may eventually lead to bone fractures (Figure 5).

Figure 5. Histological section of a microcrack found in cortical bone. Microdamage
accumulation can be initiated by cyclic loading which may lead to fractures if not repaired
by bone remodeling [48].
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If the damage is allowed to accumulate, bone strength is compromised and fracture risk is
increased; so, bone remodeling is crucial in order to remove damage and prevent bone
failure. Bone lining cells have also been thought to trigger remodeling by sensing
increases in stress and strain and relaying that information to osteocytes. The osteocytes
then recruit osteoclasts to resorb bone at that specific location [2]. Osteocytes can also
initiate remodeling by releasing chemical signals that activate remodeling after
undergoing apoptosis when sensing changes in stress [2]. The process of bone
remodeling can be divided into six stages (Figure 6):
Activation Stage. The first stage is called the activation stage and is initiated by a
chemical or mechanical stimulus that triggers progenitor cells to differentiate into
osteoclasts [2]. The osteoclasts are then recruited to a specific area to form the resorption
area of the BMU.
Resorption Stage. Once the osteoclasts are formed, the cells resorb bone by secreting
enzymes and hydrogen ions into the resorption space. Resorption occurs at a rate of
about 40 µm a day for about 3 weeks in humans [2]. Bone is resorbed in the form of a
ditch in trabecular bone and as resorption cavities or a tunnel in cortical bone [2].
Reversal Stage. The reversal stage is where the transition between osteoclasts and
osteoblasts take place. Once the osteoclasts have created a cavity for bone formation, the
cells undergo apoptosis while the osteoblasts form along the borders of the resorption
cavities. The reversal line is often called the cement line because it separates where bone
formation begins and marks the boundary of the newly forming osteons from the older
bone [2].
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Formation Stage. Bone formation occurs in two stages: matrix formation followed by
mineralization. Osteoblasts deposit an osteoid layer along the outer edge of the
resorption cavity. A canal is left in the center of the refilled cavity for the Haversian
canal. This is essential to provide the osteoblasts and osteoclasts with nutrients and waste
removal. The blood supply also transports calcium and phosphate ions into the bone
matrix to nourish the osteocytes [2]. Bone formation takes much longer than resorption,
lasting about 3 months.
Mineralization Stage. The second phase of formation is the mineralization stage. During
this stage, the unmineralized osteoid tissue becomes mineralized with hydroxyapetite [2].
The mineralization stage happens in two parts: primary mineralization occurs within a
couple days and mineralizes about 60% of the osteoid [2], and secondary mineralization
can last up to one year to mineralize the remainder of the osteiod tissue [16]. This delay
in mineralization can cause osteons to exhibit different mechanical properties [2].
Quiescence Stage. The final stage of bone remodeling occurs after resorption and
formation have completed. The BMUs begin to split apart, prompting osteoclasts to
disappear and osteoblasts to become osteocytes, bone lining cells, or disappear entirely
[2].
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Figure 6. Bone remodeling stages. (1)Activation is initiated by some stimulus which recruits
osteoclasts. (2) Osteoclasts resorb old bone in the resorption stage. (3)The reversal stage is a
transition period where resorption ends and formation begins. (4)Osteoblasts form new
bone matrix in the formation stage. (5) Osteiod tissue becomes mineralized. (6) Bone
formation and resorption are complete and osteoblasts become bone lining cells. [3]

1.5 Osteoporosis
Osteoporosis is a common skeletal disorder that is characterized by an imbalance
in bone remodeling in which the rate of bone resorption exceeds the rate of bone
formation. When more bone is being removed than is being replaced, there is an increase
in bone porosity and a loss of bone mass leading to bone fragility and an increase in
fracture risk (Figure 7). Some of the common causes of osteoporosis are: immobility,
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malnutrition, age, and a decrease in estrogen which is associated with an increase in
osteoclast activity [1]. Individuals who do not exercise and are inactive can increase their
chances of developing osteoporosis because bone disuse can lead to bone loss. Lack of
nutrients such as calcium and vitamins can also affect the health of bone because they are
essential to form the bone matrix [1]. The risk of osteoporosis is further increased with
age for both men and women; however, post menopausal women are two and half times
more likely to develop signs of osteoporosis as a result of the decrease in estrogen [5].

Figure 7. The comparison between normal and osteoporotic bone demonstrates an
increase in porosity in the diseased bone as well as a thinning of the bone tissue [6].

The National Osteoporosis Foundation has estimated that the number of people
with or at risk for osteoporosis will exceed 52 million by the year 2010 [7]. Because
osteoporosis can greatly affect the individual’s quality of life, prevention and
management of the disease is important. Treatments for osteoporosis hope to reduce
bone loss and increase bone formation. Daily doses of calcium and vitamin D can
prevent bones from becoming weaker and reduce the risk of osteoporosis. Regular

13

exercise can also stimulate bone remodeling and help build stronger bones by reducing
bone loss and increasing bone mass. Drug treatments are another effective way to treat
and prevent osteoporosis.

1.6 Bisphosphonates
Antiresorptive drugs reduce bone remodeling in hopes of increasing bone
mineralization and produce a more stable structure [8]. Bisphosphonates are a class of
antiresorptive drugs that increase bone mass and reduce fracture risk by suppressing
osteoclastic activity by inhibiting the activation of BMUs [33, 35, 36, 37] and reducing
the size of bone resorption sites [33, 38, 39, 42]. All bisphosphonates share a common
backbone structure composed of two phosphate groups bound by a carbon (Figure 8)
[11]. The phosphate groups are negatively charged, giving bisphosphonates a strong
affinity to calcium and limiting any side effects of the drug on non skeletal tissues [12].
Bisphosphonates also consists of a R1 and R2 side chain each with their own unique
structure that determines the effectiveness of the drug. The R1 side group controls the
pharmacokinetics or absorption ability of the drug while the R2 side chain determines the
mode of action and the strength of the drug [11].

Figure 8. Basic chemical structure of bisphosphonates [13].
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There are two types of bisphosphonates: nitrogenous and non-nitrogenous
bisphosphonates. First generation bisphosphonate do not contain a nitrogen group so are
referred to as non-nitrogenous. These drugs are less potent and do not target bone as well
as nitrogenous bisphosphonates [12]. Second generation bisphosphonates have a
hydroxyl R1 side chain and a nitrogen group on the R2 side chain (Table 1). The R1
hydroxyl group enhances the drugs bone binding affinity to hydroxyapatite while the R2
side group determines the anti-resorptive properties of the drug [11]. The different
nitrogen based bisphosphonates vary only at the R2 group giving each drug its own
pharmacological properties [12].
The structural variations between bisphosphonates explain their differences in
binding affinity and anti-resorptive ability [11]. The potency of each bisphosphonate is
therefore related to these factors which plays an integral role on the biological effects of
the drug. These differences are related to the ability of the drug to attach to bone, its
duration of effect, and the ability for the drug to inhibit farnesyl disphosphate synthase
(FPP synthase) for nitrogenous based bisphosphonates [11]. This mechanism of action
will be explored in more detail in a subsequent section. In vivo and in vitro studies on
rats have shown a steady increase in the potency of bisphosphonates with each
succeeding generation of drug [11]. More recent bisphosphonates like risedronate,
ibandronate, alendronate, and zolendronate were more potent in comparison to older
bisphosphonates like etidronate (Figure 9) [11]. The results of the study align with the
fact that recent bisphosphonates contain a nitrogen group on their R2 side chain which
inhibits FPP and attributes to a higher potency factor [11]. Although nitrogenous
bisphosphonates (nBPs) have a higher potency factor, certain nBPs like risedronate do
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not have as strong a binding affinity to bone as others [11]; therefore, the type of
bisphosphonate administered and the dosing schedule is important when determining how
well the drug will be diffused in the bone and its resorption ability [11]. The effects of
bisphosphonates on bone also differ in their ability to reduce bone remodeling, decrease
fracture risk, and increase mineralization depending on the drugs structure, potency,
treatment dose, length of treatment, and the bone’s initial remodeling rate [40]. Higher
doses of bisphosphonate can produce increased reductions in activation frequency of up
to 93% [33]; however, this can also result in significantly higher levels of microdamage.
Therefore, determining an optimal dosage and potency for different sites are important
when treating patients.

Table 1. Basic chemical structure of bisphosphonates. All nBPs have a hydroxyl R1 side
chain and differ only at the R2 side chain [14].
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Figure 9. Binding affinity of common bisphosphonates. Zolendronate, Alendronate,
Ibandronate, and Risedronate are nBPs and Etidronate and Clodronate are non-nBPs [11].

Alendronate is one of the most commonly prescribed bisphosphonates used for
the treatment and prevention of osteoporosis. It was approved for the treatment of
osteoporosis by the FDA in 2005 as a second generation nitrogen based bisphosphonate
manufactured by Merck & Co. under the commercial name Fosamax.
Although the exact mechanisms of action for bisphosphonates are not entirely
understood, it is clear that bisphosphonates inhibit osteoclasts and reduce bone turnover.
The effects of the drug can be categorized into three levels: tissue, cellular, and
molecular.
Tissue level. At the tissue level, bone remodeling is reduced due to a suppression in bone
resorption [15]. Because resorption and formation are coupled, by decreasing bone
turnover rate, the newly formed bone and older bone will have more time to complete
mineralization therefore increasing the mineral content of bone [16]. Bisphosphonates
increase bone mass by reducing remodeling space which reduces porous areas and creates
a positive bone balance where resorption does not exceed formation [10].
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Cellular level. At a cellular level, bisphosphonates target osteoclasts and areas of bone
resorption. Osteoclasts bind to the bone surface as usual, but when bisphosphonates are
taken up by the osteoclasts, the cytoskeleton of the cell is disrupted, causing the ruffled
border to disappear. Bone resorption declines due to the lack of a ruffled border which
plays an integral role in the osteoclasts ability to resorb bone [10].
Molecular Level. At the molecular level, nitrogen based bisphosphonates inhibit farnesyl
disphosphate synthase (FPP synthase) which is an enzyme in the mevalonate pathway
(Figure 10) [12]. FPP synthase triggers isoprenylation, a process that activates small
GTPases such as Rab, Rac, Ras, Rho [12]. GTPase is a family of enzymes that signals
proteins that regulate many properties that are important for osteoclast functions
involving vesicular trafficking, cytoskeletal arrangement, and membrane ruffling [12].
When the ruffled border of the osteoclast is interrupted, the degradation of the collagen
matrix is hindered and the osteoclast’s ability to resorb bone is inhibited [12]. High
concentration of bisphosphonate can also induce apoptosis and inhibit osteoclast
differentiation [12].
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Figure 10. Comparison of normal osteoclast function and the effects of nBPs on osteoclasts
[14].

Many experimental studies have been performed that demonstrate the effects of
alendronate on bone. Bone strength is one of the determinants of the effects of a
bisphosphonate on bone quality. The strength of bone is determined by a number of
factors including the bone volume, micro-architecture, and degree of mineralization of
bone [43]. Osteoporosis results in bone loss, which causes a weakening of the microarchitecture of bone and an increase in the activation frequency of bone remodeling
which effectively reduces the degree of mineralization [43]. In order to offset these
harmful effects, alendronate can be given to reduce the bone turnover rate.
19

A study by Mashiba et al. [33] showed that the activation frequency for bone
remodeling is suppressed after 1 year of alendronate treatment. The decrease in bone
remodeling caused microdamage accumulation to increase as well as caused a decrease in
the toughness, or the ability to absorb energy, of bone. Histological analysis on the dog
ribs also showed a reduction in resorption cavity size with the use of bisphosphonates
[33, 36].
In addition to reducing activation frequency and reducing resorption cavity area, 1
year bisphosphonate studies have also been found to increase bone mass. The underlying
effect of bisphosphonate treatment is to reduce bone resorption which in effect reduces
bone formation and reduces the overall bone turnover rate. Within a few month of
treatment, a positive bone balance is obtained and primary mineralization is increased
[41]. This reduction in bone turnover will then decrease the resorption size and allow for
secondary mineralization, both which further increase the bone density and reduce
fracture risk [41]. The effects of increasing bone mass should then increase bone strength
and improve the mechanical properties of bone [41, 44].
Using alendronate doses equivalent to those used to treat post menopausal
osteoporosis, 1 year beagle vertebral studies performed by Allen et al.’s group [17]
demonstrated a reduction in the activation frequency of bone remodeling, an increase in
microdamage, stiffness, bone volume, and mineralization with no significant effect on
the mechanical properties of bone [17]. 3 year rib studies, also performed by Allen et
al.’s group [18], showed similar results to 1 year studies; but, this study showed that
damage accumulation was not significantly higher compared to the 1 year studies [18].
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Two and three year studies have also been performed to confirm a reduction in
activation frequency and an increase in bone mineral density [36, 42, 43] when
alendronate was administered. These results are most likely caused by the increase in
mineralization [36, 43]. The results also show a reduction in fracture rate which has been
linked to improved bone strength [36, 43]. Although many experiments have been
performed that demonstrate the effects of alendronate on bone, the short time frames of
these studies necessitates additional research to determine the long term effects of
bisphosphonates.
Bisphosphonates are used to manage the rate of bone remodeling in order to
reduce the risk of fractures; however, when bone remodeling is reduced, microdamage
removal is also reduced, making the bone weaker which in the long run, may increase
fracture risk and cause bone to be more brittle [10]. Although bisphosphonates suppress
bone remodeling and the resorption of bone in order to increase tissue mineralization and
bone volume [17], they have also been associated with the impairment of microdamage
removal in canines which has been shown to lead to weaker bones [10]. An increase in
mineralization along with the increase in microdamage make bone less resistant to crack
propagation and more susceptible to fractures [10]. Although several studies have
confirmed the increase in microdamage accumulation following bisphosphonate
treatment [9,10,17,18] , three year results have shown similar levels of microdamage as
one year treatment results which suggests that microdamage accumulation is limited
beyond the initial increase after one year of treatment [18].
It is important to determine the relationship between bone remodeling and
microdamage accumulation in order to understand the long term effects of
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bisphosphonates. The lasting effects of bisphosphonates are still unclear due to the
difficulty in obtaining long term data; therefore, developing mathematical models based
on the results and relationships from short term studies can be a useful method in
predicting the effects of the drug. The purpose of this study is to simulate the effects of
alendronate on dog ribs using a computational model based on experimental data results.
The mathematical model was developed by simulating results obtained from
experimental control data, and then the effects of alendronate treatment on cortical bone
remodeling and microdamage in canine ribs were examined by modifying the simulation
in an attempt to match one and three year experimental data.

1.7 Previous Models
Understanding the variables related to bone remodeling will help to develop a
model that can determine the long term effects of alendronate on the mechanical
properties of bone. Because bone is a dynamic structure, bone remodeling algorithms
must incorporate the effects of bone adaptation to both mechanical and biological stimuli
which can be triggered by mechanical loading and fatigue microdamage [19].
Computational models have previously been developed to test hypotheses about bone’s
adaptability to both biological and mechanical stimuli. Carter et al. [20] and Huiskes et
al. [21] introduced the first finite element models to simulate the mechanical adaptability
of bone (Figure 11). Both approaches are equivalent but used different coefficients for
the daily mechanical stimulus [2]. In these models a daily mechanical stimulus based on
stress [20] or strain [21] was used alongside an error function that tracked the change in
daily mechanical stimulus in order to calculate changes in the elastic modulus over time.
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The error function is defined as the difference between the actual stress or strain stimulus
and the attractor state stimulus or the equilibrium value and is the “driving force for bone
remodeling” [45]. The new modulus was obtained by multiplying the changes in the
apparent density of the bone by a constant which would be used to calculate the new
daily mechanical stimulus for the next time step [2]. This process was repeated in an
iterative fashion for the desired period of time. Although both models were able to
simulate the mechanical adaptability of bone, neither included a cellular response.

Net apposition and
resorption rate of bone

Figure 11. Simplified diagram of Carter et al. and Huiskes et al.’s bone adaptability
model.

Hazelwood et al. [19] extended these models to include a more complete
representation of bone remodeling by incorporating bone adaptability in response to
mechanical and biological stimuli during a state of disuse (low strain) and overload (high
strain). Because bone remodeling is activated during both a state of disuse and in a state
of overload, porosity and elastic modulus were modified for each time step in order to
account for the change in loading (Figure 12). In the model, varying loads were placed
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on a representative bone volume to simulate different loading conditions that would
mimic the bone under disuse and overload which was determined by the strain [19].
During disuse (low strain), activation frequency increases, causing the bone porosity to
increase due to an elevated resorption cavity area [19]. The elastic modulus is
determined using a nonlinear relationship with porosity which is changed for each time
step in the model [19]. During overload (high strain), bone is subject to increased
damage formation due to the high loading rate. The damage removal rate has previously
been modeled by Martin [22]. Similar to the pathway for disuse, the increase in damage
triggers an increase in activation frequency which in effect adjusts the porosity of the
bone with each time step of the model.

Figure 12. Schematic of bone remodeling algorithm by Hazelwood et al.[19].

In order to simulate the effects of bisphosphonate on bone, clinical data was used
to match the results for a mathematical model. Bisphosphonate treatment will reduce the
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bone turnover rate and create a positive bone balance which allows bone mass to increase
[16]. The decrease in bone turnover will also reduce the remodeling space area and allow
bone more time to mineralize which will cause bone mineral density (BMD) to increase
[16]. Hernandez et al. [16] developed a model to compare two methods to simulate the
effects of alendronate treatment on BMD (Figure 13). The bone balance method was first
introduced by Heaney et al. [23] who modeled alendronate treatment as a decrease in
bone turnover, an increase in bone balance, and a constant bone mineralization. The
mineralization method on the other hand, modeled alendronate as a constant bone balance
and a change in both bone turnover and bone mineralization [16]. The results of both
methods were able to predict increases in BMD based on clinical studies; however, the
bone balance method attributed the majority of the BMD changes to the bone balance
while only accounting for a 6 month secondary mineralization period. Because the time
period for secondary mineralization can occur for years, the mineralization method,
which incorporated a longer secondary mineralization period, was a better indicator of
the long term changes in BMD [16]. Although both Heaney and Hernandez’s model
were able to calculate changes in BMD, both failed to include the effects of a mechanical
stimulus on bone’s adaptability.
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Figure 13. Schematic of the computational model for bone remodeling by Hernandez et al.
[16]. The model presents the progression of BMU remodeling activity in a representative
volume of trabecular bone over time. The number of active BMUs is dependent on the
number of newly formed BMUs and the number of terminating BMUs. As the BMUs
advance through the remodeling cycle, they undergo resorption, reversal, mineralization,
and a formation period, all which are tracked by the model at each time point. The sum of
all BMUs that are resorbing and forming and the resorption and formation rates are then
used to calculate the bone volume that is being resorbed or formed at each time step. The
volume formed and resorbed is then subtracted to obtain the bone volume fraction which
determines the number of new BMUs available for the next time step [16].

By incorporating Hazelwood et al.’s [19] mechanical and cellular responses with
the previously described bisphosphonate models, Nyman et al. [10] developed a
computational model to simulate the long term effects of bisphosphonate on bone mass
and microdamage accumulation in humans by modeling the effects of BMU activation
frequency suppression and BMU resorption reduction under a state of disuse,
microdamage, and estrogen deficiency [10]. The computational model was developed for
trabecular bone remodeling to examine the conditions in which bone mass would increase
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without causing microdamage to linearly increase over time. The results of the model
predicted an increase in bone volume with limited microdamage accumulation as long as
activation frequency was not completely suppressed [10]. The results were simulated by
varying both the potency of the drug and the bone balance in order to determine the
optimal amount of activation frequency suppression needed to increase bone volume.
The model predicted that microdamage accumulation was limited when activation
frequency was incompletely suppressed (Figure 14). In previous models that did not
include a disuse response, activation frequency suppression caused an increase in
microdamage and resulted in an unlimited bone gain due to the decrease in damage
removal and resorption area size respectively [10]. However, by including the disuse
response to this model, the increase in bone volume will in effect lower the strain which
triggers an increase in activation frequency due to the disuse response and decrease
damage formation [10]. The results of the model show that microdamage does not
continue to accumulate and the increase in bone mass will plateau over time [10].
Nyman et al.’s [10] model for humans is used as the foundation of the computational
model developed here for canine dog ribs, and is more closely examined in the following
chapter.
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Figure 14. Microdamage accumulation predicted by Nyman et al. [10].
Microdamage was expected to increase linearly over time when the activation frequency
was completely suppressed; however, if remodeling was incompletely suppressed,
microdamage accumulation was found to increase initially then reach a new equilibrium
over time [10].

1.8 Study Goals
The objective of this study is to develop a computational model that can simulate
the effects of alendronate treatment on canine rib remodeling and microdamage that have
been observed in experiments. Although several studies have confirmed an initial
increase in microdamage accumulation following bisphosphonate treatment, 3 year
treatment results have shown similar levels of microdamage as 1 year treatment results
which suggests that microdamage accumulation is limited beyond the initial increase at 1
year of treatment [18]. The long term effects of bisphosphonates are still unclear due to
the difficultly in obtaining long term data; therefore, developing a mathematical model
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based on experimental data and relationships from short term studies can be a useful
method in predicting the effects of the drug.
The purpose of this study is to modify previous mathematical models to match the
control, 1, and 3 year experimental data results from canine studies. The experimental
data were obtained from the Indiana University School of Medicine where the dogs were
treated with a vehicle or one of two dosages of alendronate. After 1 and 3 years, the dog
ribs were excised for analysis and quantified using standard histomorphometric
techniques. The mathematical model was developed by simulating results obtained from
the experimental control data, and then the effects of alendronate on cortical bone
remodeling and microdamage in canine ribs were examined by modifying the simulation
in an attempt to match the 1 and 3 year experimental data. Nyman et al.’s computational
model for trabecular bone adaptation based on microdamage and mechanical loading [10]
was modified in this study to simulate remodeling and bisphosphonate treatment in a
representative volume of cortical bone in the canine rib. The model incorporates
biological factors and mechanical influences to simulate the remodeling process and is
altered in this study to create a program that would match the experimental data for
remodeling in the ribs of the 1 year control animals. Using this simulation as the baseline
condition, the effects of ALN were modeled by suppressing activation frequency and
reducing the resorption area. The changes in BV/TV, damage accumulation, and Ac.f
were then simulated for 1 and 3 years and compared to experimental results. Unlike
Nyman et al.’s model which involved numerous of assumptions as to which remodeling
parameters would be used for human trabecular bone, the present model uses
experimental data for cortical canine rib bone to simulate and validate the model.
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This simulation will help in developing improved methods of predicting
bisphosphonate treatment on bone as well as determine if the long term effects of
bisphosphonate usage will indeed reduce fracture risk. The understanding of the effects
of bisphosphonate treatment on dog ribs can also aid in developing better models to
simulate the effects of bisphosphonate treatment in humans.
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CHAPTER 2: MATERIALS AND METHODS

2.1 Experimental Design
Before developing the model, histomorphometric data was obtained from
experimental results and samples given by the Indiana University School of Medicine in
order to validate the results obtained from the model. All experimental procedures were
approved by the Indiana University School of Medicine Animal Care and Use Committee
prior to beginning the study.

2.1.1 One Year Canine Experimental Methods
For the 1 year animal study, seventy-two skeletally mature female beagles (1-2
years old) obtained from Marshall Farms (North Rose, NY) were treated daily for 1 year
with oral doses of vehicle (saline control, 1ml/kg/day), risendronate sodium (RIS, 0.05,
0.10, 0.50 mg/kg/day; Proctor & Gamble Pharmaceuticals, Norwich, NY), alendronate
(ALN, 0.10, 0.20, or 1.00 mg/kg/day; Merck, RAHWAY, NJ), or raloxifene (0.50
mg/kg/day; Lilly Research Labs, Indianapolis, IN) [30]. The middle treatment doses
(RIS0.10 and ALN0.20) were determined based on clinically relevant doses used to treat
postmenopausal osteoporosis, the higher treatment doses (RIS0.5, ALN1.0) corresponds
to 5x the clinical dose used to treat osteoporosis, and the lower doses (RIS0.05,
ALN0.10, raloxifene 0.50) corresponds to approximately half these clinical treatment
doses [30]. The recommended dose of alendronate for the treatment of osteoporosis is a
70 mg tablet per week [49] which equals 0.2 mg/kg/day in a 50 kg human. Although
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several drugs were compared, for the purpose of the current study, alendronate at 0.2 and
1.0mg/kg/day will be the only drug discussed from hereon since it was the only drug used
in the 3 year study. Prior to treatment, x-rays of all dogs were taken to ensure skeletal
maturity (closed proximal tibia and lumbar vertebra growth plates) [30]. Following a 2
week acclimatization period, the dogs were divided into groups of 12 based on their body
weight [30]. The drug treatments were administered orally with a syringe for the vehicle
saline solution and by dissolving alendronate into saline each morning after an overnight
fast and two hours before feeding [30]. After 1 year of treatment, the animals were
intravenously injected with calcein (0.20 ml/kg) using a 2-12-2-5 or 2-5-2-5 labeling
schedule then euthanized by intravenously administrating sodium pentobarbital (0.22
mg/kg) [30]. The discrepancy in labeling was due to a scheduling error [30]. After
necropsy, the right ninth rib was removed and placed in 10% neutral buffered formalin
for 72 hours and then moved to a 70% ethanol solution for histological assessments [30].
The bone samples were embedded with methyl methacrylate (MMA; Aldrich,
Milwaukee, WI) and cut transversely into sections (80-100µm) using a diamond wire saw
(Histosaw; Delaware Diamond Knieves, Wilmington, DE) [30]. One cross sectional
bone sample per animal was used for the measurements using a semiautomatic system
(Bioquant OSTEO 7.20.10; Bioquant Image Analysis, Nashville, TN) attached to a
microscope equipped with an UV light source (Nikon Optiphot 2; Nikon, Tokyo, Japan)
[30]. Analysis for the 1 year study was performed by the Indiana University School of
Medicine and the results are listed below (Table 2).
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Table 2. Histomorphometric data from 1 year canine rib studies obtained from the Indiana
University School of Medicine
Vehicle
(1ml/kg/day)

Alendronate
(0.20 mg/kg/day)

Alendronate
(1.00 mg/kg/day)

Source

Formation Period, days

66.14 ± 55.12*

--

--

[30]

Activation Frequency,
#/mm2/day

0.0384 ± 0.0290*

0.0361 ± 0.0322*

0.0202 ± 0.0134*

[30]

Microdamage
(mm/mm2)

0.0169 ± 0.0189*

0.0326 ± 0.0339*

0.0332 ± 0.0393*

[30]

*

Unpublished data from specimens in [30].

2.1.2 Three Year Canine Experimental Methods
For the 3 year study, Indiana University School of Medicine performed a canine
study on thirty-six skeletally mature female beagles (1-2 years old, n=36) [24]. X-rays of
the dogs were acquired to confirm skeletal maturity (closed proximal tibia and lumbar
vertebra growth plates) [24]. Following a 2 week acclimatization period, the animals
were divided into 3 groups (n = 12/group) each treated daily for 3 years with oral doses
of vehicle (saline control, 1ml/kg/day) or alendronate (ALN, 0.2 or 1.00 mg/kg/day;
Merck and Co.) [24]. The dosing for the alendronate treatment corresponds to doses used
to treat postmenopausal osteoporosis (ALN0.2) and 5 times that amount used to treat
Paget’s disease (ALN1.0) [24]. The drug treatments were administered orally with a
syringe for the vehicle saline solution and by dissolving alendronate into saline each
morning after an overnight fast and two hours before feeding [24]. All 36 animals
completed the 3-year study with no serious complications [24]. Following 3 years of
treatment, the animals were injected with calcien (5 mg/kg as a 3% solution, IV) on a 233

12-2-5 labeling schedule prior to necropsy [24]. The animals were euthanized by
intravenous administration of sodium pentobarbital (0.22 mg/kg Beuthanasia-D Special)
and the mid section of the ninth rib was removed and preserved in 70% ethanol or 10%
neutral buffered formalin for microdamage and histomorphometric evaluation,
respectively [18]. In addition, the left eleventh rib was maintained in a saline soaked
gauze and frozen to -20 ºC for further measurements [18]. From these experiments, the
following results were obtained from the Indiana University School of Medicine and used
for the model (Table 3).

Table 3. Histomorphometric data from 3 year canine rib studies obtained from the Indiana
University School of Medicine
Vehicle
(1ml/kg/day)

Alendronate (0.20
mg/kg/day)

Alendronate 1.00
mg/kg/day)

Source

Activation Frequency,
#/mm2/day

0.00902 ± 0.00780*

0.00153 ± 0.00215*

0.00521 ± 0.00792*

[24]

Microdamage
(mm/mm2)

0.0248 ± 0.0274

0.0449 ± 0.0273

0.0408 ± 0.0216

[24]

Elastic Modulus
(MPa)

5601 ± 318

5524 ± 320

5678 ± 407

[24]

*

Unpublished data from specimens in [24].

2.2 Sample Preparation
For the histomorphometric analysis in the previous studies performed at the
Indiana University School of Medicine, the bone samples were stained en bloc with 1%
basic fuschin and embedded undecalcified in methyl methacrylate [24]. Thirty-six bone
samples from the 3 year canine rib study were obtained from the Indiana University
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School of Medicine and used to obtain further data described below. Using the facilities
at Cal Poly, two transverse sections were cut from each of the thirty-six bone samples
using a high precision bone saw (Isomet 1000; Buehler Ltd., Lake Bluff, IL), then sanded
to a thickness of around 100 micrometers using 400 grit sandpaper and mounted onto
microscope slides (Eukitt Mounting Medium; Electron Microscopy Sciences,
Hatfield,PA).

2.3 Histomorphometric Analysis
For this study, the 1 and 3 year experimental data for activation frequency (Ac.f)
and microdamage for the control and both doses of alendronate were obtained from the
Indiana University School of Medicine (Table 2 and 3). Since the 3 year bone samples
were also provided for analysis at Cal Poly, histomorphometric measurements to
determine the bone volume fraction (BV/TV) were performed for the control and both
dosages of alendronate to be used as a reference to develop the computer model. All
measurements were performed blinded. After preparing the samples for analysis, a
semiautomatic analysis system (Bioquant Image Analysis, Nashville, TN) attached to a
microscope equipped with an UV light source (Nikon, Tokyo, Japan) was used to
calculate the bone volume fraction. For each of the thirty-six bone samples, two
transverse sections were cut per bone sample (72 total) and used to measure the porous
areas of the cortical portion of the bone including the resorption spaces, Volkmann’s
canals, and Haversian canals (Figure 15). The bone’s microstructure was analyzed using
Bioquant by manually circling the porous spaces in multiple sections of the entire cortical
bone sample. The porous areas for each section were then added together and divided by
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the total cross section of the cortical bone area to obtain the porosity of the bone sample.
Because two slides were made per bone sample the porosity value for each slide was
averaged to get one value. The BV/TV was then calculated as 1 minus the porosity.

Haversian Canals

Volkmann Canal
100µm

Figure 15. Porous areas in cortical bone under fluorescent microscope.

2.4 Remodeling Simulation
Mechanical Loading. The model simulates adaptive remodeling in a 1 cm3 representative
volume of cortical rib bone under uniaxial cyclic loading. Assuming a linear relationship
between the apparent density (ρ) and the porosity (p), the elastic modulus (E) of the
representative volume was assumed to be proportional to the bone volume fraction
(BV/TV) in the following relationship,

E = E 0 × (BV / TV ) ,
a

(1)

where E0 = 6634.24, a = 5.4994, and BV/TV = (1 – p) for cortical rib bone. These values
were estimated given the available data for the elastic modulus (Table 3) and the
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measured values for the bone volume fraction (Table 5) from the 3 year experimental
study [24]. The elastic modulus and bone volume fraction values were input into Eq.1
for each treatment group (CON, ALN0.2, ALN1.0) to obtain three equations, and
linearized by applying the natural log to both sides. The general formula used was:

ln E = a ln(

BV
) + ln E 0 ,
TV

(2)

which follows the equation y = mx + b, or in this case, ln(y) = mln(x) + lnb where “m” is
the slope and corresponds with the “a” in Eq. 2 and “lnb” is the y-intercept which
corresponds to the lnE0. To find the slope and y-intercept, ln(BV/TV) versus lnE was
plotted out for each treatment group. The slope of the best fit line was adjusted, within
range of the standard deviations, to create a positive slope of a = 5.4994 (Figure 16). The
elastic modulus was calculated by taking the e of the y-intercept to obtain E0 = 6634.24.

8.625
8.62
y = 5.4994x + 8.8

lnE

8.615
8.61
8.605
8.6

-0.037

-0.0365

-0.036

-0.0355

-0.035

-0.0345

-0.034

-0.0335

-0.033

8.595
-0.0325

ln(BV/TV)

Figure 16. Proposed relationship between the bone volume fraction and the
elastic modulus.
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As described in the previous models, the porosity and elastic modulus adapt throughout
the simulation based on the effects of disuse and damage on bone remodeling (Figure
12). Although porosity is used throughout the simulation, the porosity is changed to bone
volume fraction (BV/TV = 1 – porosity) for the analysis. The disuse and damage
response are modeled using the strain and the loading rate of the representative volume.
Using Hooke’s Law, the peak strain (ε) was calculated as

ε = σ / E,

(3)

and the mechanical stimulus or loading potential was defined as

Φ = rl1× ε q ,

(4)

where rl1 is the loading frequency in cycles per day (cpd) and q is a constant that adjusts
the peak strain and loading frequency to the loading potential [10].

Porosity Transformation. The change in porosity is associated with the bone resorbing
rate (QR) and bone refilling rate (QF) for each BMU, and the number of resorbing (NR)
and refilling BMUs (NF) per unit area. The resorption rate,

Q R = AR / T R

(5)

and the refilling rate,

Q F = AF / T F

(6)
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were assumed to be linearly related with time where A, TR, and TF are the cross-sectional
area of each BMU, the resorption period, and the refilling period, respectively [26,27].
The number of resorbing BMUs (NR) and the number of refilling BMUs (NF) was found
by integrating the BMU activation frequency over the present time (t), resorption (TR),
reversal (TV) and refilling (TF) time periods accordingly,
t

NR =

∫ Acf (t ')dt '

(7)

t −TR

t − (TR +TV

NF =

)

∫ Acf) (t ')dt '

(8)

t − (TR +TV +TF

to obtain the change in porosity:

p& = Q R N R − Q F N F .

(9)

TR is the time interval beginning from the instance resorption begins to the moment the
osteoclasts stop resorbing. TV is the inactive transition period between osteoclastic to
osteoblastic activity, and TF is the interval in which osteblasts from the BMU form bone
[19].

BMU Activation Frequency. The activation frequency is the number of new BMUs
created per unit area per time (BMUs/mm2/day). BMU activation frequency was
assumed to be a function of both damage and disuse and the specific surface area (SA) in
the equation:
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Acf = (Acf ( disuse ) + Acf ( damage ) )S A .

(10)

The specific surface area is the amount of surface area available for new BMUs, which is
also defined as the bone surface per total sectional area (BS/TA). In order to ensure that
the area taken up by the new BMUs did not exceed the available surface area, SA was
divided by the maximum specific surface area (SAmax) to obtain values between 0 and 1 in
a relationship between porosity and surface area,

(

)

BA
= S A = 32.1 p − 93.9 p 2 + 134 p 3 − 101 p 4 + 28.8 p 5 / S A max ,
TS

(11)

which was developed by Martin [28]. The activation frequency was then normalized
using SA. The activation frequency for microdamage and disuse was calculated by fitting
hypothetical dose response curves for activation in response to disuse and damage [10].
The disuse response was defined as a mechanical stimulus value Φ below the equilibrium
mechanical stimulus value Φ0. During a state of disuse (Φ< Φ0), the refilling rate (QF) is
reduced; so, the area of bone formation was also reduced by adjusting the area of
formation by A[0.5+0.5(Φ/ Φ0)] to account for the reduction in refilling rate on the bone
surface [19]. The relationship between the activation frequency and the disuse and
damage was modeled assuming a sigmoidal relationship [19] between mechanical
stimulus and Acf(disuse)

Acf ( disuse ) =

Acf (max)
1 + e kb ( Φ − kc )

for Φ < Φ0.
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(12)

and damage and Acf(damage),

Acf( damage) =

( Acf0 )(Acf(max) )

Acf0 + (Acf(max) − Acf0 )e [kr

( Acf(max) )( D−D0 )/ D0 ] ,

(13)

where D0 corresponds to the initial equilibrium damage and Acf(max) was the maximum
allowable activation frequency which was intended to be much higher than the highest
average activation frequency for human cortical bone assuming that the value would not
reach this upper limit [19,29]. The sigmoidal curves were found by matching the
responses found in pharmacological applications [19]. The constants k were determined
by fitting the curves based on a range of clinical data [19]. The coefficients kr (-1.7), kb
(1.1 x 1015 cpd-1), and kc (5.739565 x 10-15 cpd) influence the shape, slope, and inflection
point of the curves respectively [19].

Microdamage Accumulation. Microdamage (D) is defined as the total crack length per
section area of bone. According to Martin [22], the rate of fatigue damage accretion is:

D& = D& F − D& R

(14)

where D& F and D& R are the damage formation and removal rates, respectively and are
equal in a state of equilibrium. The rate of damage formation was assumed to be a
function of the mechanical stimulus Φ [22] which was defined as:

D& F = k D Φ ,

(15)
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where kD is the damage coefficient and Φ = εq x rl1 is the damage potential as described
earlier. For simplicity, the strain and peak strain (ε) are equivalent [19]. Martin’s model
[22] also assumes that fatigue damage removal is proportional to the amount of damage
that exists in the following relationship:

D& R = DAcfAfS ,

(16)

where Acf is the amount of BMUs found in the representative section per day, A is the
area of all completed resorption areas, and fs is a damage removal specificity factor.
Although damage is randomly distributed in the bone, it has been shown that damage
initiates activation frequency [24], which improves the efficiency that damage is removed
compared to that of random removal [19]. To account for this, the damage removal
specificity factor was included and assumed to be 5 based on experimental results [19,
24]. By assuming there is no net damage accumulation for the baseline conditions, the
damage rate coefficient (kD) can be determined by setting D& F equal to D& R to obtain the
following equation,

k D = D0 Acf 0 Af S / Φ 0 ,

(17)

where the initial equilibrium conditions are denoted by the subscript 0.

Baseline model development. Prior to applying bisphosphonate treatment to the model,
equilibrium conditions were set based on the 1 year experimental control data. Utilizing
Nyman et al.’s [10] model for human vertebrae bone remodeling, physiological
parameters were modified in order to adjust this model for cortical bone in canine ribs.
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Pre-simulation parameters were calculated (Table 4) or estimated using data from
experimental results obtained from the Indiana University School of Medicine or past
studies. The control values were obtained by running the model until the results reached
equilibrium which took about 2000 iterations (or days). As we were unable to obtain
bone volume fraction values from 1 year experimental control animals, baseline bone
volume fraction was assumed to be similar to 3 year values for cortical rib bone at
BV/TV = 0.9675, which was obtained from histomorphometric analysis of 3 year
samples. The applied force and equivalent stress on the 100 mm2 cross-section from the
1 cm3 representative bone sample to produce the desired BV/TV was set at 13.465 N and
.13465 MPa respectively. The resulting BV/TV was 0.9651, which was within range of
the 1 year experimental control data. Both the force and stress were kept constant for the
entire bisphosphonate treatment.
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Table 4. Pre-simulation constants for bone remodeling in cortical bone prior to
bisphosphonate treatment.
Constant (units)

Description

Nominal Value

Source

Rc (mm)

Cement line radius

0.19828147

[30]

Rh (mm)

Haversian canal radius

0.0551558

[30]

Tr (days)

Resorption period

25

[19]

Tv (days)

Reversal period

5

[19]

Tf (days)

Formation period

66*

[30]

phi0 (cpd)

Initial mechanical stimulus

1.1479 x 10-14*†

[31]

por0

Initial Porosity

0.0324591*§

[24]

kb (cpd-1)

Activation frequency dose-response
coefficient
Activation frequency dose-response
coefficient

1.1 x 1015*†

[19]

5.739565 x 10-15*

[19]

kc (cpd)
fs

Damage removal specificity factor

5

[19]

d0 (mm/mm2)

Initial Damage

0.03578*

[30]

kr

Activation frequency dose-response
coefficient

-1.7*†

[19]

rl1 (cpd)

Loading rate

21600*†

[31]

q

Damage rate exponent

4

[19]

kd (mm/mm2)

Damage rate coefficient

9779300000

[19]

Initial BMU activation frequency

0.0051*

[30]

0.5

[19]

4.1905

[19]

Acf0
(BMUs/mm2/day)
Acfmax
(BMUs/mm2/day)
Samax

Maximum BMU activation
frequency
Maximum specific surface area,
normalizing constant

*

Unpublished data.
Measured data.
†
Estimated data. Constants kb and kr were determined by fitting sigmoidal curves based on the new
cortical dog rib data. rl1 was determined using a respiratory rate of 15 breaths per minute to obtain a
loading rate of 21600 cpd and phi0 was estimated from the number of loading cycles (rl1) and the
estimated strain.
§
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Simulation of Bisphosphonate. After developing a baseline model that successfully
simulated canine rib bone remodeling based on control experimental data,
bisphosphonate treatment was incorporated into the program. Bisphosphonate treatment
was modeled for 3 years based on the assumption that the treatment would reduce two
factors: activation frequency and BMU resorption area [10]. A potency variable P, where
0 ≤ P ≤ 1, was used to model the effectiveness of bisphosphonates in suppressing
remodeling. The potency was derived from pharmacokinetic properties of
bisphosphonate including its ability to suppress remodeling activation based on the
chemical structure and dosage of the drug, its ability to bind to areas of bone resorption,
its ability to be taken up by bone, and its mode of action [10] in the following equation:

(

)

P = Pmax 1 − e −τ s × N R BMU ,

(18)

where Pmax and τs are suppression coefficients that are intended to match the dosage and
structure of the bisphosphonate. These values were modified to match within 1 standard
deviation, the mean experimental data for 1 and 3 year alendronate treatment of the bone
volume fraction, activation frequency, and damage. Although these values are not
definitive, higher τ and Pmax values reflect a higher dose of alendronate and lower τ and
Pmax values indicate a lower potency. For the model, different iterations of Pmax values
ranging between 0 and 1 and tau values between 1 and 20 were used to obtain the desired
results. These ranges were determined based on past studies [10]. P was then multiplied
by the activation frequency in the equation,

Acf = (1 − P )(Acf ( disuse) + Acf ( damage) )S A ,

(19)
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to simulate bisphosphonate’s ability to suppress activation frequency [10].
The reduction in the size of the BMU resorption cavities due to bisphosphonate
treatment was also simulated by reducing the area resorbed. Starting with the control
cement line radius of 0.198 mm, different resorption cavity areas ranging from 100% of
control or no reduction, down to 50% of the control were evaluated to model
bisphosphonate treatment:

area _ r = (πRc ) ∗ percent _ area _ reduced .
2

(20)

After testing all combinations of Pmax (0-1), tau (1-20), and the percent area reduced (0.51) for bisphosphonate treatment, a Pmax = 0.3, a tau = 1, and a resorption area of 0.67 of
the control value was used for ALN0.2 and a Pmax = 0.2, a tau = 1, and a resorption area
of 0.625 was used for ALN1.0. These values were used because the results from these
combinations were found to be most closely within range of the BV/TV, Ac.f, and
microdamage for the experimental 1 and 3 years of bisphosphonate treatment for each
dosage.

Numerical implementation. The computational model was implemented in MATLAB
(Appendix A). This constitutive model relates two differential equations [Eqs. (9) and
(14)] together for porosity and damage, respectively [19]. The mechanical stimulus Φ is
the independent external force governing the model while the BMU activation frequency
is dependent on Φ, along with the damage and the porosity [Eqs. (10), (12), and (13)].
Previous studies have implemented a similar model using different numerical methods
including the forward Euler method, and varying the time increments between 0.05 to 8
days; however, the current numerical method was deemed sufficient for the present
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model. Using time steps smaller than 1 day did not significantly improve the accuracy,
therefore, an iteration period of t = 1 day was used for this model because
bisphosphonates are taken up fairly quickly [10].

2.5 Statistical Analysis
To assess the dependence of the experimental bisphosphonate treatments for 1
and 3 years, statistical analyses was performed to determine if there were variations
between the treatment groups. Using Minitab (Minitab Inc.; State College, PA), a oneway analysis of variance (ANOVA) was performed for bone volume fraction, activation
frequency, and microdamage for 1 and 3 years to compare treatment groups. P-values
less than 0.05 were considered statistically significant and signified that there was a
significant difference between the treatment groups. After completing an ANOVA, a
Tukey post-hoc test was performed to compare individual pairs of treatment groups to
determine where the significant difference lies between the paired means.

A one sample t-test analysis was performed to compare the measured data to the
simulated result for each treatment groups of bone volume fraction, activation frequency,
and microdamage. These results indicate whether the differences between the values are
statistically significant. The null hypothesis was that the simulated results were equal to
the measured results and was rejected for p < 0.05.
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CHAPTER 3: RESULTS

3.1 Experimental Bone Volume Fraction Measurements
After measuring the porosity of each of the seventy-two sample slides using
Bioquant, the bone volume fraction (BV/TV = 1 – porosity) was calculated. Because two
sections were cut from each of the thirty-six bone samples, the average BV/TV of each
sample was calculated and is listed in Table 5 with its treatment group. The final BV/TV
values for each treatment group are summarized in Table 6. These results were
calculated by taking the mean with standard deviations of all the data from each of the
three treatment groups.
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Table 5. Measured 3 year data by treatment for bone volume fraction (BV/TV).*
Sample # Treatment BV/TV
60809
ALN1.0
0.9745
60750
ALN1.0
0.9743
59244
ALN1.0
0.9595
59230
ALN0.2
0.9534
59210
CON
0.9612
59234
CON
0.969
59238
ALN1.0
0.9618
59211
ALN1.0
0.9695
59235
ALN0.2
0.9724
59257
CON
0.9674
59219
ALN0.2
0.9618
59315
CON
0.9592
59256
ALN0.2
0.9592
59258
ALN0.2
0.9677
59231
ALN1.0
0.9636
59236
ALN1.0
0.9558
60657
ALN1.0
0.9589
60628
CON
0.9717
60034
CON
0.9654
60592
ALN0.2
0.9677
59536
ALN1.0
0.9596
60642
ALN0.2
0.9783
60593
ALN1.0
0.958
60636
ALN0.2
0.9685
59677
CON
0.9662
60630
CON
0.9729
60707
CON
0.9678
60629
ALN0.2
0.9615
60631
ALN0.2
0.973
59239
ALN0.2
0.9639
60641
ALN1.0
0.9751
60632
CON
0.9767
60643
ALN1.0
0.9597
60645
ALN0.2
0.9697
60644
CON
0.9631
60667
CON
0.9675
*

Unpublished measured data
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Table 6. Mean ± SD for the measured 3 year data.

Bone volume
fraction (BV/TV)

CON (1ml/kg/day)

Alendronate (0.20
mg/kg/day)

Alendronate 1.00
mg/kg/day)

.96754 ± 0.00489

.96642 ± 0.00683

.96415 ± 0.00718

3.2 Simulation Bone Volume Fraction Results
For the simulation, the bone volume fraction (BV/TV) for both doses of
alendronate (ALN0.2 mg/kg/day and ALN1.0 mg/kg/day) remained fairly constant
throughout the 3 years of bisphosphonate treatment as was expected from the
experimental data. Figure 17 illustrates graphs for 1 and 3 years of ALN0.2 and ALN1.0
treatment groups. Although 1 year experimental control data was not obtained from the
Indiana University School of Medicine, 3 year experimental control results were used
instead because 1 and 3 year bone volume values were assumed to be similar. The
model’s results for the bone volume percentage were consistent with the experimental
data (Table 7). All simulated results matched within one standard deviation of the
measured values.

Table 7. Model simulation and experimental measurements for bone volume fraction of the
canine rib bone after 1 and 3 years by treatment.
Bone Volume Fraction
1 year

3 years

Experimental

Simulated

Experimental

Simulated

CON

0.968 ± 0.00489

0.9651

0.968 ± 0.00489

0.9651

ALN0.2

0.966 ± 0.00683

0.9649

0.966 ± 0.00683

0.9651

ALN1.0

0.964 ± 0.00718

0.9649

0.964 ± 000.718

0.9651
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a
Bone Volume Fraction for ALN0.2
98
97.5
Simulation

BV/TV (%)

97

Experimental
96.5
96
95.5
95
94.5
CON

ALN0.2 (1 year)

ALN0.2 (3 year)

b.
Bone Volume Fraction for ALN1.0
98
97.5

BV/TV (%)

97

Simulation
Experimental

96.5
96
95.5
95
94.5
CON

ALN1.0 (1year)

ALN1.0 (3year)

Figure 17. Simulation and experimental measurement results (mean and SD) for BV/TV for
(a) control (CON) and ALN0.2 at 1 and 3 years and (b) control (CON) and ALN1.0 at 1 and
3 years.
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3.3 Simulation Activation Frequency Results
The results of the computational model for the control and 1 year cortical rib data
for the activation frequency were consistent with experimental measurements (Table 8).
The model was able to predict the 1 year experimental results for both ALN0.2 and
ALN1.0 along with the experimental results for ALN1.0 at 3 years, but overestimated the
results for ALN0.2 at 3 years. In the simulation, alendronate suppressed activation
frequency for bone remodeling for both doses of drug and remained fairly constant over
the span of 3 years of treatment. While the simulation predicted that activation frequency
remains mainly constant over the 3 years, the experiments show decreases between 1 and
3 years. Although not to a great degree, remodeling was suppressed in the model almost
immediately after bisphosphonate treatment was introduced. By 1.5 years, activation
frequency had reached near constant for both alendronate doses. The representative
graphs of both the simulated and experimental treatment data with its corresponding error
bars can be seen in Figures 18.

Table 8. Model simulation and experimental measurements for activation frequency of the
canine rib bone after 1 and 3 years of ALN treatment.
Activation Frequency (BMUs/mm2/day)
1 year

3 years

Experimental

Simulated

Experimental

Simulated

CON

0.0384 ± 0.0290

0.0098

0.00902 ± 0.0077

0.0098

ALN0.2

0.0361 ± 0.0322

0.009698

0.00153 ± 0.00215

0.0099

ALN1.0

0.0202 ± 0.0134

0.009698

0.00521 ± 0.00792

0.01
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a.

Activation Frequency for ALN0.2
Ac.f (#BMU/sq. mm/year)

25
20
Simulation

15

Experimental

10
5
0
CON

ALN0.2 (1year)

ALN0.2 (3year)

b.
Activation Frequency for ALN1.0

Ac.f (#BMU/sq. mm/year)

25

20

Simulation

15

Experimental
10

5

0
CON

ALN1.0 (1year)

ALN1.0 (3year)

Figure 18. Simulation and experimental measurement results (mean and SD) activation
frequencies for (a) control (CON) and ALN0.2 for 1 and 3 years or treatment and (b)
control (CON) and ALN1.0 for 1 and 3 years of treatment.
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3.4 Simulation Microdamage Results
The results of the computational model for the control, 1, and 3 year rib data for
microdamage were consistent with experimental measurements (Table 9). The model
was able to predict an initial increase in damage for both bisphosphonate treatment doses
before leveling off slightly after 1 year (Figure 19). Microdamage begins to increase
almost immediately after bisphosphonate treatment with a percent increase of 51.2%
(ALN0.2) and 58.9% (ALN1.0) from the start of initiating bisphosphonate treatment
(CON) to 3 years of treatment. For ALN0.2, the modeled results show a percent increase
of 8.3% from 1 to 3 years of bisphosphonate treatment and for ALN1.0, the modeled
results show a percent increase of 10.2% from 1 to 3 years of bisphosphonate treatment.
Although the simulated damage is not as high as the damage obtained from the
experimental data, the overall trend correlates with experimental data which showed that
the increase in microdamage at 3 years was not significantly different compared to the 1
year results. Both experimental and simulated microdamage results are shown for 1 and
3 years of alendronate treatment in Table 9. A condensed table of all parameters of
interest (BV/TV, Ac.f, and damage) can be found in Appendix B.

Table 9. Model simulation and experimental microdamage measurements in the canine rib
bone after 1 year and 3 years of ALN treatment.
Microdamage (mm/mm2)
1 year

3 years

Experimental

Simulated

Experimental

Simulated

CON

0.0169 ± 0.0189

0.0129

0.0248 ± 0.0280

0.0129

ALN0.2

0.0326 ± 0.0339

0.018

0.0449 ± 0.0273

0.0195

ALN1.0

0.0332 ± 0.0393

0.0187

0.0408 ± 0.0216

0.0206

54

a.
Microdamage for ALN0.2

Damage (mm/sq. mm)

0.08
0.07
Simulation
1 year
3 years

0.06
0.05
0.04
0.03
0.02
0.01
0
-300

-150

0

150

300

450

600

750

900

1050 1200

Time (days)

b.
Microdamage for ALN1.0

Damage (mm/sq. mm)

0.08
0.07
Simulation
1 year
3 years

0.06
0.05
0.04
0.03
0.02
0.01
0
-300

-150

0

150

300

450

600

750

900

1050 1200

Time (days)

Figure 19. Experiment (mean ± SD) and simulation graphs for damage with
bisphosphonate treatment starting at t = 0 (a) ALN0.2, (b) ALN1.0
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3.5 Statistical Analysis
A one-way ANOVA was performed on the bone volume fraction, activation
frequency, and microdamage to test for significant differences between experimental
treatment groups. An ANOVA was only performed for experimental treatment groups so
that any variation in the experimental results could be noted. The results are displayed in
Table 10 and Table 11 for the ANOVA.

Table 10. 1 year ANOVA results for measured activation frequency and damage by
treatment
CON

ALN0.2

ALN1.0

P

Activation Frequency
(BMUs/mm2/year)

0.0384 ± 0.0290

0.0361 ± 0.0322

0.0202 ± 0.0134

0.196

Damage (mm/mm2)

0.0169 ± 0.0189

0.0326 ± 0.0339

0.0332 ± 0.0393

0.374

Table 11. 3 year ANOVA results for measured bone volume fraction, activation frequency,
and damage by treatment
CON

ALN0.2

ALN1.0

P

Bone Volume Fraction

0.968 ± 0.00489

0.966 ± 0.00683

0.964 ± 0.00718

0.426

Activation Frequency
(BMUs/mm2/year)

0.00901 ± 0.0271

0.00153 ± 0.00215

0.00521 ± 0.00792

0.0286

Damage (mm/mm2)

0.0228 ± 0.271

0.0449 ± 0.0273

0.0408 ± 0.216

0.0914

All p-values for 1 year of alendronate treatment were greater than 0.05 which
indicates that the variation between treatment groups were not significant. The p-values
for 3 year alendronate treatment showed that there is a significant difference between the
treatment groups for the activation frequency which had a p-value of 0.0286. To
determine where the difference lies between each treatment, individual Tukey
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comparisons were performed for the 3 year activation frequency. The p-values for the
Tukey comparisons show that the difference in treatment group found in the ANOVA test
lies in the CON/ALN0.2 comparison with a p = 0.0039. The results for the Tukey
comparisons are presented in Table 12.

Table 12. P-values for individual Tukey comparison for activation frequency for 3 years of
treatment.
Comparisons

P

CON and ALN0.2

0.0039

CON and ALN1.0

0.2472

ALN0.2 and ALN1.0

0.1337

A separate comparison between the experimental results of ALN0.2 and ALN1.0
for 1 and 3 years for activation frequency shows that all p-values are less than 0.05 which
indicates that the 1 and 3 year data for both treatment groups are significantly different
(Table 13). A comparison between the experimental results for ALN0.2 and ALN1.0 for
1 and 3 years for microdamage found that all p-values were greater than 0.05 which
signifies that the 1 year experimental data is similar to the 3 year experimental data for
each treatment group (Table 14).

Table 13. P-values for activation frequency comparing 1 and 3 year experimental values.
Comparisons

P

1 year CON vs 3 year CON

0.0026

1 year ALN0.2 vs 3 year ALN0.2

0.0012

1 year ALN1.0 vs 3 year ALN1.0

0.0029
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Table 14. P-values for damage comparing 1 and 3 year experimental values.
Comparisons

P

1 year CON vs 3 year CON

0.5427

1 year ALN0.2 vs 3 year ALN0.2

0.3365

1 year ALN1.0 vs 3 year ALN1.0

0.5651

A one sample t-test analysis was performed to compare the measured
experimental values to the simulated results for bone volume fraction, activation
frequency, and damage. The null hypothesis for each of the following t-tests was that the
measured experimental value is equal to the simulated results, which represents the mean
value. For the bone volume fraction, the p-value of all treatment groups (CON, ALN0.2,
and ALN1.0) for 1 and 3 years of treatment was greater than 0.05 so the null was not
rejected, which implies that the measured and simulated results are statistically similar
for all treatment groups (Table 15).
Table 15. P-values for t-test for bone volume fraction for 1 and 3 years by treatment.
1 year

3 years

P

P

CON

0.112

0.112

ALN0.2

0.458

0.518

ALN1.0

0.726

0.657

T-tests for the 1 year CON group for activation frequency resulted in a p < 0.05
suggesting that there is a significant difference between the measured and simulated
values with the 1 year experimental results being higher than the 1 year modeled result.
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Similarly, a p value less than 0.05 was found for the ALN0.2 treatment group for 1 and 3
years of treatment and for the ALN1.0 treatment group for 1 year (Table 16). The null
hypothesis was rejected for these cases. The 3 year ALN1.0 treatment group for
activation frequency resulted in a p > 0.05 indicating a similarity between the measured
and simulated results, so the null hypothesis was not rejected.

Table 16. P-values for t-test for activation frequency for 1 and 3 years by treatment.
1 year

3 years

P

P

CON

0.006

0.7324

ALN0.2

0.016

0.0001

ALN1.0

0.02

0.06

T-test results for microdamage (Table 17) yielded p values greater than 0.05 for
all 1 year treatment groups and the CON at 3 years, which indicate that the null was not
rejected and that the measured and simulated results are statistically similar. For ALN0.2
and ALN1.0 treatment groups at 3 years, p = 0.008, which implies that there is a
significant difference between the measured and simulated results for both cases with the
experimental damage result higher than the modeled result for both treatment groups.
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Table 17. P-values for t-test for damage for 1 and 3 years by treatment.
1 year

3 years

P

P

CON

0.484

0.2335

ALN0.2

0.164

0.008

ALN1.0

0.227

0.008
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CHAPTER 4: DISCUSSION

Osteoporosis is a skeletal disease that occurs when the amount of bone resorption
exceeds that of bone formation. Without treatment, bone becomes more porous and
fracture risk is increased. Bisphosphonates are commonly used to treat bone diseases
such as osteoporosis by reducing resorption activity [17]. The objective of this study was
to modify a previous mathematical model for bone remodeling which incorporated a
bisphosphonate algorithm, in order to simulate the effects of alendronate on canine rib
remodeling and microdamage after 1 and 3 years of treatment. To do so, empirical data
for 1 and 3 year studies were supplied by Allen et al. [24, 30] from the Indiana University
School of Medicine, and utilized to confirm the accuracy of the model. The current study
uses the results from the control experimental data for dog ribs as a baseline to create a
model that simulates the effects of ALN for a 3 year period. The importance of
developing a model is to predict long term outcomes without having to carry out long
term experimental tests. Because canine bone remodeling dynamics are similar to human
bone remodeling, this canine model can be used to draw parallels to the drugs effects on
human bones [32].

4.1 Bone Volume Fraction
The model predicts a slight increase in the bone volume fraction for both
treatment doses from one to three years. The results comply with the original assumption
that the 1 and 3 year experimental data were similar, which allowed the three year bone
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volume measurements to be used in place of the one year data. To validate this
assumption, an ANOVA test was performed between experimental treatment groups
(CON, ALN0.2, and ALN1.0). The p-value of 0.426 indicates that the results from each
treatment group are not significantly different. Results from the computer model indicate
that the BV/TV for both doses of alendronate was fairly constant throughout the 3 years
of bisphosphonate treatment and the simulation was able to successfully match all
experimental data within one standard deviation. The small increase from one to three
years of treatment denotes a decrease in the bone’s porosity which is due to the
suppression of osteoclast activity. This is consistent with studies that have shown an
increase in bone mass following treatments of bisphosphonate [10].

4.2 Activation Frequency
The model results for activation frequency for the control, 1 year ALN0.2 and
ALN1.0, and 3 year ALN1.0 were within range of the experimental data; however,
activation frequency for ALN0.2 for 3 years was not consistent with the experimental
measurements. As predicted by past experimental studies, bisphosphonate usage
suppressed bone remodeling for both modeled doses of alendronate. While the
simulation was able to show decreases in bone remodeling for both treatment doses after
1 year of treatment, the decrease was not nearly as drastic as the results seen in the
experimental study and remained fairly constant between 1 and 3 years, which is in
contrast to the experimental results. Despite this, the model was able to match all but one
of the experimental data, which overestimated ALN0.2 for the three years of treatment.
The one-way ANOVA for activation frequency for 3 years of treatment found that there
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was a discrepancy between the three treatment groups (CON, ALN0.2, and ALN1.0) with
a p-value less than 0.05. This result shows that there is a statistically significant
difference between the 3 year experimental treatment groups and that there is less than a
5% chance of obtaining these results assuming the null hypothesis is true. Performing a
Tukey comparison between individual 3 year experimental treatment groups showed that
the difference came from the control group. The current model predicts that the
activation frequency for the 1 and 3 year control treatment is similar and did not account
for the actual change seen in the experimental measurements. The unpublished 3 year
study by Burr et al. [24] obtained a control activation frequency of 0.00901
BMUs/mm2/day, which is 4 times less than the 1 year control activation frequency used
for the model (0.03841 BMUs/mm2/day). This disparity in 1 and 3 year control values
may explain some of the inconsistencies of the model results. The one-sample t-test
statistical analysis determined that 3 year CON and ALN1.0 for the measured and
simulated results are similar; however, all 1 year treatment groups (CON, ALN0.2, and
ALN1.0) and the 3 year ALN0.2 for the measured and simulated results are statistically
different with p-values less than 0.05. Although the 1 year measured and simulated
results were found to be statistically different, all 1 year modeled results were within 1
standard deviation of the experimental results.

4.3 Microdamage Accumulation
The effect of bisphosphonates on microdamage accumulation has been a major
issue concerning the long term use of the drug because increases in microdamage can
lead to bone fragility. Studies have shown a relationship between the suppression of
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bone remodeling and microdamage accumulation over a treatment period of 1 year [17,
33]. Because patients generally undergo osteoporosis treatment drugs for longer than 1
year, it is important to determine the effects of the drug for a longer time period. Three
year studies performed by Allen et al. [18, 24] show that although treatment group
microdamage levels increase above the control group, damage does not significantly
increase after 1 year of alendronate treatment. The computer model predicts that damage
accumulation is greatest early during bisphosphonate treatment, due to the initial
suppression of bone resorption, and eventually reaches a new equilibrium level after 1
year. Although the increase in damage is not as high as the measured results, the overall
shape of the curve is consistent. The increase in damage was previously thought to
impair the mechanical properties of bone [34]; however, recent experimental studies
show that while the initial increase in microdamage may contribute to alterations in bone
properties at 1 year of treatment, other factors like increased mineralization and bone
volume appear to impede the harmful effects of damage accumulation in the long run
[24]. The simulation results are consistent with the experimental data, which suggest that
damage increases up to 1 year of treatment and then levels off thereafter. The results of
the simulation suggest that since bisphosphonates do not cause a further increase in
microdamage accumulation after 1year of treatment, ALN may not lead to increased bone
fragility associated with microdamage long term. These results are seen in 3 year
experimental studies as well.
Logically, it makes sense that microdamage increases until a new equilibrium is
reached between the amount of damage formation and damage removal because
bisphosphonates inhibit bone remodeling. The computational model results for the 1 and
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3 year rib data for all treatment groups were consistent with experimental measurements.
One-sample t-test statistical analyses confirm that the simulated 1 year microdamage
results for the CON, ALN0.2, and ALN1.0 treatment groups were similar to the 1 year
experimental measurements with p > 0.05. The 3 year simulated control group also
showed similarities to the 3 year experimental control; however, the t-tests for the three
year ALN0.2 and ALN1.0 treatment groups rejected the null hypothesis with p values
less than 0.05. Although the ALN0.2 and ALN1.0 treatment groups did not satisfy the
null hypothesis in this case, as observed in the graph (Figure 13), both results are within 1
standard deviation of the experimental measurement data.

4.4 Limitations and Future Model Considerations
The present study was able to simulate the effects of alendronate treatment on
bone remodeling; however, limitations to the model must be considered when
interpreting the results. Although the general mechanisms of bisphosphonate are
simulated in the model, the entire range of the drugs response is not taken into account
due to its complexity and the lack of understanding of the exact mechanism of action that
bisphosphonates have in the body. Theoretical models require many of assumptions and
guesswork which involve verifying the results of the model with experimental data.
As indicated by Hernandez et al. [16], bone mineralization is a major contributor
of increases in BMD than simply decreasing area resorbed as done in the current model.
Bisphosphonate treatment reduces the bone turnover rate in bone which allots more time
for mineralization to take place thus allowing secondary mineralization to play an
important role in BMD. By limiting the number of osteoclasts that resorb bone, bone is
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allowed more time to mineralize before being resorbed thus resulting in increases in bone
mass. Because changes in resorption area and mineralization are both factors in
increased BMD, future models should include both methods when determining the effects
of bisphosphonates on bone remodeling.
Another possible improvement is the elastic modulus and the bone volume
fraction relationship. For the current model, the equation was estimated using only the
empirical data given for the 3 year bisphosphonate dog rib study. If more information
was available for the 1 year experimental studies including the elastic modulus and the
bone volume fractions from each treatment group, the modulus-BV/TV relationship
could be improved by comparing the 1 and 3 year results and creating a more accurate
relationship.
The current model assumes that the ability of BMUs to target damage removal or
the specificity factor fs is constant; but, this is not necessarily accurate since areas of
resorption with microdamage have been shown to be reduced with alendronate treatment
[10]. If fs were to be varied according to the microcrack initiation, damage removal may
decrease compared to the current results.
Also, bone formation was assumed to be normal prior to bisphosphonate
treatment. However, this does not accurately represent osteoporotic bone which
corresponds to higher levels of bone resorption and a decrease in bone formation.
Modeling osteoporotic bone from the start could greatly improve the current model.
Another limitation of the current model is that it was assumed that the control
experimental result for bone volume fraction, activation frequency, and microdamage
were assumed to be the same for 1 and 3 year. In actuality, the control for 1 and 3 year
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experimental studies vary greatly. This assumption will affect the modeled activation
frequency result most, as this 3 year experimental control varied greatly compared to the
1 year experimental control data. The model would significantly benefit by modifying
the program to take this into account. By allowing the simulation to reach the three year
experimental control, the 3 year model results may improve and more accurately
represent the 3 year experimental results.
Furthermore, the current study only simulates remodeling under a constant
applied stress in a representative section of bone rather than modeling the entire rib bone
or developing finite element models that could allow a more accurate remodeling
response by allowing more precise loading conditions and provide better analysis of
different strain rates on different sections of bone. Making these modifications in the
model could greatly improve future understanding of bisphosphonates and its long term
effects on bone.

4.5 Conclusion
The goal of the study is to develop a computational model to determine the effects
of bisphosphonate treatment on remodeling dynamics by matching the results of 1 and 3
year experimental data for bone remodeling and damage in a canine rib model. The
results from the simulation are as follows:
•

Previous experimental studies have shown that bisphosphonate treatment reduces
fracture risk by increasing bone mass [17, 33]. The model predicted a slight
increase in bone volume fraction for both doses (ALN0.2 and ALN1.0) of
bisphosphonate treatment over a three year period.
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•

The purpose of taking alendronate is to reduce bone porosity by decreasing bone
resorption. Bisphosphonates do this by suppressing osteoclast activity and in
effect bone remodeling which decreases the activation frequency as shown in the
model.
 Although the degree of reduction in activation frequency for the computer
model did not match the value seen in the experiments, 1 and 3 year
ALN1.0 and 3 year ALN1.0 treatment doses were within range of the
measured results.

•

Because bisphosphonates suppress bone remodeling, microdamage accumulation
has been shown to increase at 1 year of treatment [17, 18, 24, 33]; however, 3
year experimental results show that although microdamage increases after initial
bisphosphonate treatment, damage does not continue to increase and rather
reaches a plateau after around 1 year.
 The model was able to reflect the recent 3 year canine studies performed
by Allen et al. [18, 24]. All simulated model results for microdamage
support the findings obtained from previous experimental studies.

Future experimental studies investigating longer time periods of bisphosphonate
treatment are necessary in order to enhance and validate the computer model to better
predict the long term effects of bisphosphonate usage. Longer experimental studies are
also needed to better understand the relationship between bone remodeling suppressant
drugs and bone health. Improved computational models are also beneficial to more
accurately predict bone remodeling. This is important in order to ensure that the long
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term effects of alendronate treatment are safe and effective for the use in osteoporotic
patients. These simulations will help in developing improved methods of predicting
bisphosphonate treatment on bone as well as determine if the long term effects of
bisphosphonate usage will indeed increase bone mass and reduce fracture risk. The
understanding of the effects of bisphosphonate treatment on dog ribs can also aid in
developing better models to simulate the effects of bisphosphonate treatment in humans.
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APPENDIX A: MATLAB CODE

%Bone Remodeling Simulation with Bisphosphonate Treatment
%modified from Jeffery Nyman
%Emily Huang 7May2009
%
clear
clc
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%% Remodeling parameters %%
% Cement line radius
% Haversian canal radius
% Resorption period
% Reversal period
% Formation period
% Porosity partition for cortical to trabecular
% bone: Change resorption area & Disuse
% Porosity partition for cortical to trabecular bone:
trab2 = 0.097267787;
% Change in stiffness constants
phi0 = 0.00000000000001147913;
% Equilibrium stimulus
% initial cortical porosity (from 3 year rib study)
por0 = 0.0324591;
%por0 = 0.2;
% Initial trabecular porosity (for human vertebra
% bone)
sa0 = ((((28.8*por0-101)*por0+134)*por0-93.9)*por0+32.1)*por0;
% Initial surface area
% Adjusts resorption rate to match apposition rate
phc = 0.0324591;
% for cortical bone (i.e. assumes resorption
% process includes void spaces
Rc = 0.19828147;
Rh =.0551558;
Tr = 25;
Tv = 5;
Tf = 66;
trab1 = 0.2;

%% Activation frequency conditions %%
% Describes Ac.f versus disuse and Ac.f versus damage curves %
Acfmax1 = 0.5;
% Maximum Ac.f due to damage
% Maximum Ac.f due to disuse
Acfmax2 = 0.5;
% Normalizes specific area
samax = 4.1905;
% Equilibrium Ac.f for disuse
Acfdis0 = 0.0;
Acfdam0 = 0.0224693284;
% Equilibrium Ac.f for damage
Acf0 = (Acfdam0 + Acfdis0)*sa0/samax ; % Equilibrium Ac.f
% Remodeling coefficient (obtained from curve
kb = 1100000000000000;
% fitting clinical data)
kc = phi0/2;
% Remodeling coefficient (obtained from curve
% fitting clinical data)
%% Damage conditions %%
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fs = 5;
% Damage repair factor
% Initial equilibrium damage
d0 = 0.03578;
if por0 <= trab1
kd = d0*Acf0*(pi*Rc^2)*fs/phi0 ;
% Equilibrium damage constant
else
kd = 0.5*d0*Acf0*(pi*Rc^2)*fs/phi0;
end
kr = -1.7;

% Remodeling coefficient (obtained from curve
% fitting clinical data)

%% Mechanical conditions %%
Area = 100;
rl1= 21600;
q = 4;
change = 0;
chgper = 1;
days = 2000;
bis_days = 365*3;
dt = 1;

% Cross-sectional area of bone
% Frequency of loading in no. of cycles per day
% Exponent of mechanical stimulus
% Percent change in force
% Time period of force change
% Time length to equilibrium
% Time length for bisphosphonate
% Time step; One day

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%% Prior conditions before start of simulation %%
for t=1:(Tr+Tv+Tf)
por(t) = por0;
% Porosity
if por(t) <= trab2
modulus(t) = 6634*(1-por(t))^5.49; %Stiffness of bone if cortical
else
modulus(t) = 6634*(1-por(t))^5.49; %Stiffness of bone if trabecular
end
Phi(t) = phi0;
strain(t) = (phi0/rl1)^0.25;
stress(t) = modulus(t)*strain(t);
Force(t) = stress(t)*Area;
SA(t) = sa0/samax;
Df(t) = kd*phi0;
Dr(t) = d0*Acf0*(pi*Rc^2)*fs;

% Mechanical stimulus
% Principal strain
% Principal stress
% Force on bone
% Normalizes Ac.f by available surface area
% Damage formation rate
% Damage removal rate

if por(t) > trab1
Dr(t) = 0.5*Dr(t);
end
D(t) = d0;
NfBMU(t) = Acf0*Tf;
NrBMU(t) = Acf0*Tr;

% Damage
% No. of refilling BMUs
% No. of resorbing BMUs

76

if por(t) <= trab1
% Mineral apposition rate
Qf(t) = pi*(Rc^2-Rh^2)/Tf;
% Mineral resorption rate
Qr(t) = pi*Rc^2/Tr;
QrNr(t) = (1-phc)*Qr(t)*NrBMU(t); % Amount bone removed
% Amount of bone added
QfNf(t) = Qf(t)*NfBMU(t);
else
Qf(t) = 0.5*pi*Rc^2/Tf;
Qr(t) = 0.5*pi*Rc^2/Tr;
QrNr(t) = Qr(t)*NrBMU(t);
QfNf(t) = Qf(t)*NfBMU(t);
end
Qnet(t) = QfNf(t)-QrNr(t);
removed
Acfdam(t) = Acfdam0;
Acfdis(t) = Acfdis0;
Acf(t) = 0.03841;
TIME(t) = t;
end

% Difference between mineral added and mineral
% Ac.f due to damage
% Ac.f due to disuse
% Total inital Ac.f

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%% Constants for bisphosphonate treatment %%
%Pmax = 0;
Pmax = .2;
%Pmax = 1;
tau= 1;

% Pmax values between 0 and 1
% Tau values between 1 and 20

%percent_area_reduced = 1;
% percent area of CON area reduced b/w 0.5 and 1
% percent_area_reduced = 1/1.1;
% percent_area_reduced = 1/1.2;
% percent_area_reduced = 1/1.3;
% percent_area_reduced = 1/1.4;
% percent_area_reduced = 1/1.5;
percent_area_reduced = 1/1.6;
% percent_area_reduced =1/1.7;
% percent_area_reduced = 1/1.8;
% percent_area_reduced = 1/1.9;
% percent_area_reduced = 1/2;

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%% Simulation %%
for t=(Tr+Tv+Tf+1):((days)+ bis_days)
TIME(t) = t;
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%% Mechanical conditions update %%
if por(t-1) <= trab2
modulus(t) = 6634*(1-por(t-1))^5.49;
else
modulus(t) = 6634*(1-por(t-1))^5.49;
end
Force(t) = 13.465;
stress(t) = Force(t)/Area;
strain(t) = stress(t)/modulus(t);

%Stiffness of bone if cortical
%Stiffness of bone if trabecular

% Stress on bone
% Strain on bone

%% Porosity update %%
Phi(t) = (strain(t)^q)*rl1;
if por(t-1) <= 0.2
area_f = pi*(Rc^2-Rh^2);

%Calculate current stimulus

%Formation area of cortical bone (Cement
% line to Haversian canal)
%Inital period
%Resorption area if cortical

if (t <= days)
area_r = pi*Rc^2;
else
area_r = (pi*Rc^2) * percent_area_reduced ; %Resorption area if cortical & on
% Bisphosphonate
end
else
area_f = 0.5*pi*Rc^2;

%Formation area of trabecular
% bone (half of osteon area w/o
% pore)
%Initial period
%Resorption area if trabecular

if (t <= days)
area_r = 0.5*pi*Rc^2;
else
area_r = (pi*Rc^2) * percent_area_reduced; %Resorption area if trabecular on
% bisphosphonate
end
end
%% Calculate change in damage level and update %%
Df(t) = kd*Phi(t);
Dr(t) = D(t-1)*Acf(t-1)*area_r*fs;
D(t) = D(t-1) + (Df(t) - Dr(t))*dt;

%Damage formation rate
%Damage removal rate
%Damage update

%% Calculate demand for new BMUs (Ac.f) %%
if D(t) >= d0
Acfdam(t) = (Acf0*Acfmax1)/(Acf0+(Acfmax1-Acf0)*exp(kr*Acfmax1*(D(t-1)%Damage stimulus
d0)/d0));
else
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Acfdam(t) = Acf0*D(t-1)/d0;
end

if Phi(t) >= phi0
Acfdis(t) = 0;

% No demand for additional
% remodeling if not in disuse

else
Acfdis(t) = Acfmax2/(1+exp(kb*(Phi(t)-kc)));

% Demand for remodeling when
% bone is in disuse

end
sa = ((((28.8*por(t-1)-101)*por(t-1)+134)*por(t-1)-93.9)*por(t-1)+32.1)*por(t-1);
%Surface area
SA(t)= sa/samax;
%Update Ac.f
Acf(t) = (Acfdam(t) + Acfdis(t))*SA(t);

%% Calculate daily amount of bone removed per resorbing BMU %%
%% Include less refilling on trabecular surfaces in disuse %%
% Formation area
% Resorption area

ab = area_f;
ac = area_r;
Qf(t) = ab/Tf;
Qr(t) = ac/Tr;
if Phi(t) < phi0
if por(t-1) > trab1
Qf(t) = (0.5 + 0.5*(Phi(t)/phi0))*Qf(t);

% For trabecular bone, formation
% rate decreases in disuse

end
end

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%% Bisphosphosphonate effect
%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
if (t > days)
P = Pmax*(1-exp(-1*tau*NrBMU(t-1)));
% P = 1;

%Bisphosphonate treatment period
% Remodeling is completely
% suppressed
% Bisphosphonate suppressed
% activation frequency

Acf(t)=(1-P)*(Acfdam(t)+Acfdis(t))*SA(t);
end

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%% Calculate number of refilling BMUs for current day %%

79

%% Calculate number of resorbing BMUs for current day %%
NfBMU(t) = NfBMU(t-1) + (Acf(t-Tr-Tv) - Acf(t-Tr-Tv-Tf))*dt;
NrBMU(t) = NrBMU(t-1) + (Acf(t) - Acf(t-Tr))*dt;

if NfBMU(t) < 0
NfBMU(t) = 0;
end
if NrBMU(t) < 0
NrBMU(t) = 0;
end

%% Calculate net amount of bone added per day %%
QfNf(t) = NfBMU(t-1)*Qf(t-1) + (Acf(t-Tr-Tv)*Qf(t-Tr-Tv) - Acf(t-Tr-Tv-Tf)*Qf(t-Tr-Tv-Tf))*dt;
% amount of bone added
QrNr(t) = NrBMU(t-1)*Qr(t-1) + (Acf(t)*Qr(t) - Acf(t-Tr)*Qr(t-Tr))*dt;
% amount of bone removed
if por(t-1) <= 0.20
Qnet(t) = QfNf(t) - (1-phc)*QrNr(t);
else
Qnet(t) = QfNf(t)-QrNr(t);
end

%% Calculate change in porosity %%
por(t) = (por(t-1) - Qnet(t))*dt;
uplim = 0.99;
blim = 0.0;
if por(t) >= uplim;
por(t) = uplim;
elseif por(t) <= blim;
por(t) = blim;
end

end
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
figure(1);
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plot(TIME,por);
title('Porosity');
xlabel('Time (days)');
ylabel('Void space/Total area');
figure(2);
plot(TIME,Acf);
title('Ac.f');
xlabel('Time (days)');
ylabel('Activation frequency (# BMU/day/mm2)');
figure(3);
plot(TIME,Phi);
title('Phi');
xlabel('Time (days)');
ylabel('Mechanical stimulus');
figure(4);
plot(TIME,D);
title('Damage');
xlabel('Time (days)');
ylabel('Cr.S.Dn (mm/mm2)');
figure(5);
plot(TIME,Qnet);
title('change in bone');
xlabel('Time (days)');
ylabel('delta Porosity');
figure(6);
plot(TIME, kd);
%% Outputs %%
BoneVolumeFraction = (1-por(t))
ActivationFrequency = Acf(t)
Damage = D(t)

for t=1:days + bis_days
Dataout(t,:) = [TIME(t),por(t),Phi(t),strain(t),stress(t),Force(t),SA(t),Df(t),Dr(t),D(t),
NfBMU(t),NrBMU(t),Qf(t),Qr(t),QrNr(t),QfNf(t),Qnet(t),Acfdam(t),Acfdis(t),Acf(t),kd];
end
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APPENDIX B: COMPREHENSIVE TABLE OF ALL SIMULATED AND MEASURED DATA

CON

ALN0.2 (1 YEAR)

ALN0.2 (3 YEARS)

ALN1.0 (1 YEAR)

ALN1.0 (3 YEARS)

Experimenta
l

Simulate
d

Experimenta
l

Simulated

Experimenta
l

Simulated

Experimental

Simulated

Experimental

Simulated

BV/TV

0.968 ±
0.00489

0.9651

0.966±
0.00683

0.9649

0.966 ±
0.00683

0.9651

0.964 ±
0.00718

0.9649

0.964 ±
0.00718

0.9651

Ac.f
(BMU’s/mm
2
/day)

0.0384 ±
0.0290

0.0098

0.0361 ±
0.0322

0.009698

0.00153 ±
0.00215

3.6135

0.0202 ±
0.0134

0.009698

0.00521 ±
0.00792

0.01

Damage
(mm/mm2)

0.0169 ±
0.0189

0.0129

0.0326 ±
0.0339

0.018

0.0449 ±
0.0273

0.0195

0.0332 ±
0.0393

0.0187

0.0408 ±
0.0216

0.0206
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